West Pharmaceutical Services (WST) official guidance

•Full-year 2026 capital spending guidance is updated to a range of $215 million to $220 million, down from the prior range of $250 million to $275 million.

Our expectations of $250 million-$275 million in the Capital Expenditures remains unchanged for the year.

Capital spending guidance is unchanged from a range of $250 million to $275 million.

We remain on track with our expectations of $250 million-$275 million for the year, even as we increase our revenue guidance, which I'll talk about shortly.

Capital spending guidance is unchanged from a range of $250 million to $275 million.

Capital expenditures for the year of $286 million are down $91 million year-on-year, and we expect another step down in 2026 to a range of $250 million-$275 million as we move back to the construct of spending 6%-8% of sales in CapEx.

Full-year 2026 capital expenditures are expected to be in the range of $250 million to $275 million.

We do feel comfortable that we're going to be back to the 6%-8% of sales corridor for CapEx, but heavily weighted towards the high-value product components part of our business.

To help with your models, we are projecting $8 million of net interest income, a tax rate for the full year slightly lower than 19%, and roughly 71.5 million diluted shares outstanding for the full year.

To help with your models, we are now projecting $7 million in net interest income, a 19% tax rate for the full year, and roughly 71.5 million diluted shares outstanding for the full year.

We are assuming roughly $10 million in net interest income, a 20.25% tax rate for the full year, and 72.7 million diluted shares outstanding for the full year.

To help with your models, we are projecting $8 million of net interest income, a tax rate for the full year slightly lower than 19%, and roughly 71.5 million diluted shares outstanding for the full year.

To help with your models, we are now projecting $7 million in net interest income, a 19% tax rate for the full year, and roughly 71.5 million diluted shares outstanding for the full year.

We are assuming roughly $10 million in net interest income, a 20.25% tax rate for the full year, and 72.7 million diluted shares outstanding for the full year.

•The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $9.38 to $9.48, up from the previous range of $8.85 to $9.05.

We now anticipate organic revenue growth to be 10%-11% for the full year and adjusted EPS to be in the range of $8.85-$9.05.

The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $8.85 to $9.05, up from the previous range of $8.40 to $8.75.

This results in an adjusted earnings per share to be between $8.40 to $8.75 for the year, up 15%-20% year-over-year.

The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $8.40 to $8.75, up from the previous range of $7.85 to $8.20.

Adjusted earnings per share is forecast to be between $7.85-$8.20, representing double-digit growth at the midpoint.

Full-year 2026 adjusted-diluted EPS is expected to be in a range of $7.85 to $8.20, representing growth of 7.7% to 12.5%.

To help with your models, we are projecting $8 million of net interest income, a tax rate for the full year slightly lower than 19%, and roughly 71.5 million diluted shares outstanding for the full year.

To help with your models, we are now projecting $7 million in net interest income, a 19% tax rate for the full year, and roughly 71.5 million diluted shares outstanding for the full year.

The positive revenue mix is helping us to further expand our margins, and our guidance now incorporates over 200 basis points of operating margin expansion as compared to 2025.

If we look at our full year, from last guide to this guide, probably another 50 basis points improvement year-over-year. A very nice expansion.

We expect to expand margins over 100 basis points, with margins increasing over the course of the year, driven by HVP components and the SmartDose divestiture.

◦Organic net sales growth guidance increased to a range of 11.3% to 11.6%, up from the prior range of 10% to 11%.

For the year, we now anticipate revenue to be in the range of $3.345 billion-$3.38 billion, growing 10%-11% organically, which is up from 7%-9% previously.

Reported net sales growth is anticipated to be in the range of 8.8% to 10.0%, and organic net sales growth is expected to be in the range of 10.0% to 11.0%.

For the year, we now anticipate revenue to be in the range of $3.295 billion-$3.35 billion, up $78 million at the midpoint. This reflects an increased organic revenue growth range of 7%-9% for the year.

Reported net sales growth is now anticipated to be in the range of 7.2% to 9.0%, and organic net sales growth is expected to be in the range of 7% to 9%.

For the year, we anticipate revenue to be in the range of $3.215 billion-$3.275 billion. Reported growth is 4.6%-6.5%, and with FX and the SmartDose adjustment roughly offsetting to get to our organic growth range of 5%-7% for the year.

Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%.

•The Company is increasing its full-year 2026 net sales guidance range to $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion.

For the year, we now anticipate revenue to be in the range of $3.345 billion-$3.38 billion, growing 10%-11% organically, which is up from 7%-9% previously.

The Company is increasing its full-year 2026 net sales guidance range to $3.345 billion to $3.380 billion, up from $3.295 billion to $3.350 billion.

For the year, we now anticipate revenue to be in the range of $3.295 billion-$3.35 billion, up $78 million at the midpoint. This reflects an increased organic revenue growth range of 7%-9% for the year.

The Company is increasing its full-year 2026 net sales guidance range to $3.295 billion to $3.350 billion, which continues to assume a mid-year close for the sale of SmartDose® 3.5mL to Abbvie, up from $3.215 billion to $3.275 billion.

For the year, we anticipate revenue to be in the range of $3.215 billion-$3.275 billion. Reported growth is 4.6%-6.5%, and with FX and the SmartDose adjustment roughly offsetting to get to our organic growth range of 5%-7% for the year.

Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie.

| Reported-diluted EPS (U.S. GAAP) | $6.79 | $9.01 to $9.26 | 32.7% to 36.4% |

| Reported-diluted EPS (U.S. GAAP) | $6.79 | $8.15 to $8.50 | 20.0% to 25.2% |

The Company is introducing its third-quarter 2026 adjusted-diluted EPS guidance range of $2.14 to $2.24.

Non-GLP-1 HVP components are expected to grow low double digits and make up just over 5 points of total company growth, while GLP-1 HVP components is expected to be in the mid- to high teens.

In the proprietary segment, we expect HVP components to continue to be the primary driver of revenue growth. We now anticipate this business to grow low to mid-teens organically for the year, accounting for about seven points of the total company growth at the midpoint of guidance.

We expect HVP components to be the primary driver of our revenue growth. We expect this segment to grow high single digit to low double digits organically for the year, accounting for just over 5 points of total company growth at the midpoint of our guidance.

Non-GLP-1 HVP components are expected to grow low double digits and make up just over 5 points of total company growth, while GLP-1 HVP components is expected to be in the mid- to high teens.